Aptimmune Biologics Inc Profile last edited on: 1/29/2024
CAGE: 63Y75
UEI: S7N6W8FTTD39
Business Identifier: Prophylactic measures against viral diseases of swine 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 13
County: Champaign
Congr. District: 13
County: Champaign
Public Profile
Aptimmune Biologics specializes in the development and application of prophylactic measures against viral diseases of swine. Their current focus is bringing into the market effective prophylaxis against Porcine Reproductive and Respiratory Syndrome (PRRS) virus. Aptimmune utilizes novel technologies to create effective vaccines against PRRSV such as the proprietary pig alveolar macrophage cell line ZMAC.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2017 | 2 | USDA | $699,948 | |
| Project Title: A new class of porcine reproductive and respiratory syndrome (PRRS) autogenous vaccine produced in a novel porcine macrophage cell line | ||||
Key People / Management
Aaron Gilbertie -- CEO
Federico Zuckermann -- Chief Scientific Officer and Founder
Gabriela Calzada-Nova -- Senior Scientist
Gary Durack -- Director of Operations
Federico Zuckermann -- Chief Scientific Officer and Founder
Gabriela Calzada-Nova -- Senior Scientist
Gary Durack -- Director of Operations
